Vitaspring Biomedical CO LTD

VitaSpring Biomedical Co. Ltd. announced the engagement of JP Centurion & Partners PLT as its new independent registered public accounting firm, effective August 19, 2025.

VitaSpring Biomedical reports a net loss of $75,844 for Q1 2026, with substantial doubt cast on its ability to continue as a going concern due to a significant working capital deficit and minimal cash reserves.

VitaSpring Biomedical's Q3 2025 report highlights significant financial challenges, including a substantial working capital deficit and a material weakness in internal controls, raising substantial doubt about its ability to continue as a going concern.

VitaSpring Biomedical's Q2 2026 report highlights significant financial challenges, including a severe working capital deficit and minimal cash, raising substantial doubt about its ability to continue as a going concern.

VitaSpring Biomedical reported zero revenue for the first quarter of fiscal year 2025, with a net loss of $80,541 and a significant increase in working capital deficiency.

VitaSpring Biomedical reports no revenue for Q3 2025, with a widening working capital deficit and ongoing concerns about its ability to continue as a going concern.

VitaSpring Biomedical Co., Ltd. filed its Form 10-Q for the quarter ended July 31, 2024, reporting no revenue and a net loss, while continuing to rely on related-party financing.

VitaSpring Biomedical Co., Ltd. filed its annual report, highlighting substantial doubt about its ability to continue as a going concern due to a lack of revenue and significant liabilities.

VitaSpring Biomedical Co., Ltd. has filed its delayed Form 10-K for the fiscal year ended January 31, 2025, detailing its development-stage status, ongoing financial challenges, and strategic focus on regenerative medicine.

VitaSpring Biomedical Co. Ltd. reported no revenue for fiscal year 2024, a net loss of $1.1 million, and a substantial accumulated deficit, raising significant doubt about its ability to continue as a going concern.

VitaSpring Biomedical Co. Ltd. reported a net loss of $4.16 million for the fiscal year ended January 31, 2023, a significant decline from the prior year's profit, as it focuses on R&D and seeks additional capital.